IBio (NYSEMKT:IBIO) initiates its
second COVID-19 vaccine program, IBIO-201, which combines antigens
derived from the SARS-CoV-2 spike protein fused with the company’s
patented lichease booster molecule (adjuvant).
It launched its first program, IBIO-200, a SARS-CoV-2 Virus-Like Particle vaccine candidate, several months ago.
https://seekingalpha.com/news/3580431-ibio-launches-second-covidminus-19-vaccine-program
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.